Ambu CEO on stream of launches: "Won't be easy, but we're building an ecosystem"
In the next three years, Ambu expects to launch four times as many products as during its prior strategy period, and the CEO sees clear advantages to scaling the firm at this speed. At the same time, the company needs to succeed with the ecosystem of products which the CEO plans to establish at hospitals worldwide.
BY ULRICH QUISTGAARD, TRANSLATED BY NIELSINE NIELSEN
Ambu is pushing the pedal to the metal to establish itself on the single-use endoscope market.
In the last three years, the medtech company has introduced five new scopes, and in the next three years, it plans to launch 20 new products.
During this month’s meeting of the CHMP, the EMA’s expert committee, a total of nine new drugs have been recommended while six drugs have had indication extensions accepted. Two treatments have been rejected.
After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.